Innate Pharma S.A. (NASDAQ:IPHA – Get Free Report) saw a significant drop in short interest in September. As of September 15th, there was short interest totalling 59,700 shares, a drop of 8.3% from the August 31st total of 65,100 shares. Based on an average daily trading volume, of 6,600 shares, the short-interest ratio is currently 9.0 days.
Analyst Ratings Changes
Several research analysts recently issued reports on IPHA shares. Evercore ISI upgraded shares of Innate Pharma to a “strong-buy” rating in a research report on Monday, September 16th. HC Wainwright reiterated a “buy” rating and set a $11.50 target price on shares of Innate Pharma in a research report on Friday, September 13th.
View Our Latest Analysis on Innate Pharma
Innate Pharma Stock Performance
About Innate Pharma
Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.
Featured Stories
- Five stocks we like better than Innate Pharma
- Comparing and Trading High PE Ratio Stocks
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- How Can Investors Benefit From After-Hours Trading
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- There Are Different Types of Stock To Invest In
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.